Cancer
📧 Sign up to get email alerts when something new happens for Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-25EMA Authorised: Akynzeo (netupitant;palonosetron hydrochloride) — Helsinn Birex Pharmaceuticals Ltd
The EMA authorised Akynzeo (netupitant and palonosetron hydrochloride) for vomiting, nausea, cancer-related indications.
-
EMA approval · 2026-08-20EMA Authorised: Instanyl (Fentanyl citrate) — Istituto Gentili S.r.l.
EU authorization for Instanyl (fentanyl citrate) by Istituto Gentili S.r.l. for pain and cancer-related indications.
-
EMA approval · 2026-08-19EMA Authorised: Nivestim (filgrastim) — Pfizer Europe MA EEIG
Nivestim (filgrastim) has been authorised by EMA for hematopoietic stem cell transplantation and cancer indications.
-
EMA approval · 2026-08-04EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG
The EMA authorises Silapo (epoetin zeta) by Stada Arzneimittel AG for treating anemia associated with cancer, chronic kidney failure, and bl…
-
EMA approval · 2026-07-29EMA Authorised: PecFent (fentanyl) — Gruenenthal GmbH
PecFent (fentanyl) by Gruenenthal GmbH has been authorised for use in pain and cancer indications in the EU.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-20EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG
Authorised status for Retacrit (epoetin zeta) by EMA for use in anemia-related indications, including kidney failure, cancer-related anemia,…
-
EMA approval · 2026-07-15EMA Authorised: PecFent (fentanyl) — Gruenenthal GmbH
EMA authorizes PecFent (fentanyl) by Gruenenthal GmbH for pain and cancer indications.
-
EMA approval · 2026-07-15EMA Authorised: Rozlytrek (Entrectinib) — Roche Registration GmbH
The EMA authorises Rozlytrek (entrectinib) for cancer, including non-small cell lung carcinoma, under conditional approval.
-
EMA approval · 2026-07-14EMA Authorised: Dyrupeg (pegfilgrastim) — CuraTeQ Biologics (Malta) Limited
Dyrupeg (pegfilgrastim) has been authorised by the EMA for neutropenia and cancer indications.
-
EMA approval · 2026-07-14EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics (Malta) Limited
Zefylti (filgrastim) has been authorised by EMA for use in neutropenia, hematopoietic stem cell transplantation, and cancer indications.
-
EMA approval · 2026-07-03EMA Authorised: NeoRecormon (epoetin beta) — Roche Registration GmbH
NeoRecormon (epoetin beta) has been authorised by the EMA for related indications in chronic kidney failure, anemia, cancer, and autologous …
-
EMA approval · 2026-06-05EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH
Authorised status for Zarzio (filgrastim) by Sandoz GmbH in the EU, covering hematopoietic stem cell transplantation and cancer indications.
-
EMA approval · 2026-03-18EMA Authorised: Akynzeo (netupitant;palonosetron hydrochloride) — Helsinn Birex Pharmaceuticals Ltd
EMA authorised Akynzeo, a fixed-dose combination of netupitant and palonosetron hydrochloride, for prevention of vomiting and nausea associa…
-
EMA approval · 2026-03-18EMA Authorised: Pelmeg (pegfilgrastim) — Mundipharma Corporation (Ireland) Limited
EMA authorised Pelmeg, a pegfilgrastim biosimilar by Mundipharma, to reduce the duration of neutropenia and the risk of febrile neutropenia …
-
EMA approval · 2026-03-02EMA Authorised: Nivestim (filgrastim) — Pfizer Europe MA EEIG
EMA has authorized Nivestim (filgrastim) from Pfizer Europe MA EEIG as a biosimilar to treat neutropenia in cancer patients and in the conte…
-
EMA approval · 2026-03-02EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG
EMA authorised Retacrit (epoetin zeta) as a biosimilar epoetin for the treatment of anemia in chronic kidney disease and cancer, among other…
-
EMA approval · 2026-02-24EMA Authorised: Vivlipeg (pegfilgrastim) — Biosimilar Collaborations Ireland Limited
The EMA authorised Vivlipeg, a biosimilar pegfilgrastim. The product is indicated for neutropenia and related febrile neutropenia in cancer …
-
EMA approval · 2026-02-24EMA Authorised: Zoledronic Acid Accord (zoledronic acid monohydrate) — Accord Healthcare S.L.U.
The EMA authorised Zoledronic Acid Accord (zoledronic acid monohydrate) for hypercalcemia, prevention of fractures in bone disorders, and ca…
-
EMA approval · 2026-01-19EMA Authorised: Effentora (fentanyl) — Phoenix Labs Unlimited Company
The EMA has authorised Effentora (fentanyl) by Phoenix Labs Unlimited Company for the treatment of breakthrough cancer pain in opioid-tolera…
-
EMA approval · 2026-01-13EMA Authorised: Aranesp (darbepoetin alfa) — Amgen Europe B.V.
EMA authorised Aranesp (darbepoetin alfa) for anemia associated with cancer and chronic kidney disease.
-
EMA approval · 2025-12-08EMA Authorised: Neulasta (pegfilgrastim) — Amgen Europe B.V.
EMA authorised Neulasta (pegfilgrastim) by Amgen Europe B.V. to reduce the risk of neutropenia, febrile neutropenia, and chemotherapy-induce…
-
EMA approval · 2025-11-05EMA Authorised: Ivemend (fosaprepitant) — Merck Sharp & Dohme B.V.
EMA authorised Ivemend (fosaprepitant) by Merck Sharp & Dohme B.V. for prevention of chemotherapy-induced vomiting in cancer patients.
-
EMA approval · 2025-10-24EMA Authorised: Emend (aprepitant) — Merck Sharp & Dohme B.V.
The EMA authorised Emend (aprepitant) by Merck Sharp & Dohme B.V. for prevention of vomiting and nausea in cancer patients, including postop…
-
EMA approval · 2025-09-29EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics s.r.o
The European Medicines Agency authorised Zefylti (filgrastim) as a biosimilar for neutropenia, hematopoietic stem cell transplantation, and …
-
EMA approval · 2025-08-13EMA Authorised: Instanyl (Fentanyl citrate) — Istituto Gentili S.r.l.
The EMA has authorised Instanyl (fentanyl citrate) by Istituto Gentili S.r.l. for the management of pain, including cancer-related pain.